Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Chem Lab Med ; 52(11): 1649-55, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24937505

RESUMEN

BACKGROUND: Only a limited number of cytotoxic drugs have shown activity in metastatic colorectal carcinoma. Patupilone is a novel agent with promising activity in this common cancer. Diarrhea represents the dose-limiting toxicity of patupilone. Measurement of intestinal permeability is one of the potential methods of non-invasive laboratory assessment of gastrointestinal toxicity. METHODS: We have assessed intestinal permeability by measuring absorption of lactulose, mannitol and xylose in 27 previously treated patients with metastatic colorectal cancer enrolled in a phase I trial of patupilone. RESULTS: Lactulose/mannitol and lactulose/xylose ratios increased after the treatment. Significantly higher lactulose/mannitol ratio was observed in patients who had severe diarrhea. Moreover, patients who subsequently had an adverse event of grade 3 or higher had significantly higher baseline lactulose/mannitol or lactulose/xylose ratios. CONCLUSIONS: Measurement of intestinal permeability using the lactulose/mannitol test may represent a biomarker for the monitoring, or even prediction of toxicity of cytotoxic drugs, including patupilone.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias del Colon/tratamiento farmacológico , Epotilonas/uso terapéutico , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/farmacología , Neoplasias del Colon/patología , Diarrea/etiología , Epotilonas/efectos adversos , Epotilonas/farmacología , Femenino , Humanos , Mucosa Intestinal/metabolismo , Intestinos/efectos de los fármacos , Lactulosa/metabolismo , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Masculino , Manitol/metabolismo , Persona de Mediana Edad , Permeabilidad/efectos de los fármacos , Xilosa/metabolismo
2.
Hepatogastroenterology ; 59(114): 366-71, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22353500

RESUMEN

BACKGROUND/AIMS: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Among the side-effects of cetuximab hypomagnesaemia has been described, but the information is still limited. METHODOLOGY: We have evaluated retrospectively serum magnesium, potassium, calcium, creatinine and albumin in 51 consecutive patients with metastatic colorectal carcinoma treated with cetuximab, mostly combined with irinotecan-based combination chemotherapy. RESULTS: A significant decrease of serum magnesium, potassium, calcium and corrected serum calcium, creatinine and albumin concentrations was already evident one week after the start of treatment. Hypomagnesaemia of any grade was detected in 56% of evaluable patients, but grade 3 or grade 4 hypomagnesaemia was observed in 6% and 4% of patients, respectively. Grade 1 hypokalemia was detected in 47%, grade 3 in 17% and grade 4 hypokalemia was detected in 6% of the patients. Among evaluable patients grade 1 hypocalcaemia was detected in (36%), grade 2 hypocalcaemia in 42%, grade 3 in 4% and grade 4 in 13% of patients. Baseline hypocalcaemia of grade 1 or higher was associated with significantly inferior survival. CONCLUSIONS: Asymptomatic hypomagnesaemia, hypokalemia and hypocalcaemia are common in metastatic colorectal carcinoma patients treated with cetuximab. Hypocalcaemia is a predictor of poor prognosis.


Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Antineoplásicos/efectos adversos , Carcinoma/tratamiento farmacológico , Neoplasias Colorrectales/tratamiento farmacológico , Magnesio/sangre , Enfermedades Metabólicas/inducido químicamente , Inhibidores de Proteínas Quinasas/efectos adversos , Adulto , Anciano , Anticuerpos Monoclonales Humanizados , Enfermedades Asintomáticas , Biomarcadores/sangre , Calcio/sangre , Carcinoma/enzimología , Carcinoma/mortalidad , Carcinoma/secundario , Cetuximab , Neoplasias Colorrectales/enzimología , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Creatinina/sangre , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/metabolismo , Femenino , Humanos , Hipocalcemia/sangre , Hipocalcemia/inducido químicamente , Hipopotasemia/sangre , Hipopotasemia/inducido químicamente , Estimación de Kaplan-Meier , Masculino , Enfermedades Metabólicas/sangre , Enfermedades Metabólicas/mortalidad , Persona de Mediana Edad , Potasio/sangre , Estudios Retrospectivos , Albúmina Sérica/metabolismo , Albúmina Sérica Humana , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
3.
Acta Medica (Hradec Kralove) ; 54(3): 127-30, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22250484

RESUMEN

Only a few cases of pneumocystis pneumonia (PCP) in Cushing's syndrome have been published in the literature so far. In the majority of these patients, the pneumonia occurred after reduction of the hypercortisolism with medicamentous treatment. We report two cases of PCP during conservative treatment of hypercortisolism. We describe clinical, imaging and laboratory findings in two patients and review published cases of pneumocystits pneumonia in Cushing's syndrome. A 60-year-old woman and 20-year-old man with Cushing's syndrome due to ectopic ACTH syndrome were treated at our department. Both developed pneumocystis pneumonia early after treatment with ketoconazole and ethomidate bromide had been introduced and the levels of cortisol rapidly decreased. PCP prophylaxis in patients with high cortisolemia should be started before treatment of hypercortisolism in current practice. Gradual lowering of plasma cortisol should also reduce the risk of infection by Pneumocystis jiroveci.


Asunto(s)
Síndrome de Cushing/tratamiento farmacológico , Neumonía por Pneumocystis/etiología , Adulto , Síndrome de Cushing/sangre , Etomidato/uso terapéutico , Femenino , Humanos , Hidrocortisona/sangre , Cetoconazol/uso terapéutico , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/etiología , Neumonía por Pneumocystis/inmunología , Neumonía por Pneumocystis/prevención & control , Adulto Joven
4.
Int J Radiat Biol ; 84(6): 523-30, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18470751

RESUMEN

PURPOSE: Apoptosis is significantly controlled by proteins of Bcl-2 (B-cell lymphoma 2) family promoting cell death or maintaining cell survival. We selected two representatives of Bcl-2 family (anti-apoptotic Mcl-1 - myeloid cell line-1 and pro-apoptotic Bid - Bcl-2 homology domain 3 interacting death agonist), cytochrome c (cyt-c), and two initial caspases (-8 and -9) to evaluate their function in ionizing radiation (IR)-induced apoptosis in human leukaemic cell lines diverging in p53 (TP53 tumor suppressor gene) status. MATERIALS AND METHODS: A total of 30 microg of proteins of whole-cell lysates or 10 microg of mitochondrial protein fractions were electrophoretically separated and analyzed by Western-blotting. RESULTS: Here we show that in both HL-60 (p53 null) and MOLT-4 (p53 wild type) leukaemic cells the amount of Mcl-1 initially increased after irradiation by sublethal but not by lethal dose and later (when apoptosis occurred) it decreased in a dose-dependent manner. Caspase-8 was cleaved and afterwards the amount of Bid decreased as it was truncated. We also found cyt-c release from the inner mitochondrial membrane space into cytoplasm to be dose-dependent and it was followed by induction of apoptosis. In the p53-null cells caspase-8 was activated prior caspase-9, whereas the cells harboring p53 exhibited a simultaneous activation of both initial caspases. CONCLUSION: IR induced a decrease in Mcl-1, activation of Bid, caspase-8, and -9, and release of cyt-c. Presented data indicate that both extrinsic and intrinsic apoptosis signalling pathways were activated in HL-60 and MOLT-4 cells upon exposure to IR regardless to the p53 status.


Asunto(s)
Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Caspasa 8/metabolismo , Caspasa 9/metabolismo , Citocromos c/metabolismo , Rayos gamma/efectos adversos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Apoptosis , Línea Celular Tumoral , Activación Enzimática/efectos de la radiación , Humanos , Proteína 1 de la Secuencia de Leucemia de Células Mieloides
5.
J Gastroenterol Hepatol ; 23(12): 1934-40, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18717760

RESUMEN

BACKGROUND AND AIM: Melibiose/rhamnose permeability test is used for noninvasive intestinal mucosa barrier testing. However, the possible escape route of the absorbed saccharides through either intact or impaired blood-biliary barriers has not so far been explored. The objective of the present study was therefore two-fold: First, to describe in detail the biliary pharmacokinetics of melibiose and rhamnose in rats; second, to evaluate the changes of both sugars' pharmacokinetics upon impairment of the blood-biliary barrier by acute extrahepatic cholestasis in rats. METHODS: Bile duct obstructed (BDO), sham-operated and intact (unoperated) male Wistar rats were administered, 24 h after the appropriate intervention, with a single intravenous dose of melibiose and rhamnose, and a 4-h pharmacokinetic study was performed. RESULTS: In intact animals, the biliary excretion of melibiose and rhamnose was only 0.06% and 0.4% of the administered dose, respectively, while the urinary excretion accounted for 70.6% and 61.7%, respectively. In BDO animals, the biliary excretion rate of both saccharides, especially that of melibiose, was increased with a consequent 4.4-fold rise of the biliary melibiose/rhamnose ratio, the accepted paracellular permeability indicator. Both, the renal clearance of melibiose and the urinary melibiose/rhamnose ratio remained uninfluenced by cholestasis. CONCLUSION: The present study is the first to describe in detail pharmacokinetic parameters and the biliary excretion of melibiose and rhamnose in healthy and cholestatic rats. The altered melibiose/rhamnose biliary excretion ratio in BDO rats indicates that the test is able to detect the impairment of the blood-biliary barrier in acute extrahepatic cholestasis.


Asunto(s)
Canalículos Biliares/metabolismo , Bilis/metabolismo , Colestasis/metabolismo , Melibiosa/farmacocinética , Ramnosa/farmacocinética , Uniones Estrechas/metabolismo , Enfermedad Aguda , Animales , Colestasis/diagnóstico , Cromatografía Líquida de Alta Presión , Técnicas de Diagnóstico del Sistema Digestivo , Modelos Animales de Enfermedad , Inyecciones Intravenosas , Masculino , Melibiosa/administración & dosificación , Melibiosa/orina , Permeabilidad , Ratas , Ratas Wistar , Ramnosa/administración & dosificación , Ramnosa/orina , Regulación hacia Arriba
6.
Acta Biochim Pol ; 54(2): 281-7, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17565390

RESUMEN

ATM kinase (ATM) is essential for activation of cell cycle check points and DNA repair in response to ionizing radiation (IR). In this work we studied the molecular mechanisms regulating DNA repair and cell death in human T-lymphocyte leukemic cells, MOLT-4. Apoptosis was evaluated by flow-cytometric detection of annexin V. Early apoptotic cells were determined as sub-G1 cells and late apoptotic cells were determined as APO2.7-positive ones. Proteins involved in ATM signalling pathway were analysed by Western-blotting. We observed a rapid (0.5 h) phosphorylation of ATM declining after 6 h after irradiation by all the doses studied (1.5, 3.0, and 7.5 Gy). Checkpoint kinase-2 (Chk-2) was also phosphorylated after 0.5 h but its phosphorylated form persisted 4, 2, and 1 h after the doses of 1.5, 3.0, and 7.5 Gy, respectively. The amount of p53 protein and its form phosphorylated on Ser-392 increased 1 h after irradiation (1-10 Gy). The lethal dose of 7.5 Gy caused an immediate induction and phosphorylation of p53 after 0.5 h post-irradiation. At the time of phosphorylation of p53, we found simultaneous phosphorylation of the oncoprotein Mdm2 on Ser-166. Neither ATM nor its downstream targets showed a dose-dependent response after 1 h when irradiated by the doses of 1-10 Gy. MOLT-4 cells were very sensitive to the effect of IR. Even low doses, such as 1.5 Gy, induced apoptosis 16 h after irradiation (evaluated according to the cleavage of nuclear lamin B to a 48-kDa fragment). IR-induced molecular signalling after exposure to all the tested doses was triggered by rapid phosphorylation of ATM and Chk-2. Subsequent induction of p53 protein and its phosphorylation was accompanied by concomitant phosphorylation of its negative regulator, oncoprotein Mdm2, and followed by induction of apoptosis.


Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Proteínas de Unión al ADN/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal/efectos de la radiación , Linfocitos T/metabolismo , Linfocitos T/efectos de la radiación , Proteínas Supresoras de Tumor/metabolismo , Apoptosis/efectos de la radiación , Proteínas de la Ataxia Telangiectasia Mutada , Línea Celular Tumoral , Quinasa de Punto de Control 2 , Daño del ADN , Reparación del ADN , Rayos gamma , Humanos , Leucemia de Células T/metabolismo , Fosforilación , Tolerancia a Radiación , Linfocitos T/citología , Proteína p53 Supresora de Tumor/metabolismo
7.
Hepatogastroenterology ; 53(67): 100-5, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16506385

RESUMEN

BACKGROUND/AIMS: Although liver is a common site of metastases in breast cancer, isolated liver metastases in patients with disseminated breast cancer are rare. The role of liver-directed therapies in these patients is based on data derived from retrospective analysis of case series. METHODOLOGY: We have reviewed the records of 8 patients with liver metastases and a history of breast cancer treated at our institution over a period of 11 years with regional chemotherapy administered through surgically implanted port systems. RESULTS: Three of the patients also had a history of second primary colorectal carcinoma. One patient had evidence of extrahepatic spread. All patients were treated by regimens based on the combination of 5-fluorouracil and folinic acid. Three patients were also treated by cytoreductive procedures. The median survival times from the diagnosis and port systems implantation were 34 months and 31 months, respectively. CONCLUSIONS: Our data support the use of regional intraarterial chemotherapy in patients with metastatic breast cancer limited to the liver.


Asunto(s)
Neoplasias de la Mama/patología , Quimioterapia del Cáncer por Perfusión Regional , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Anciano , Femenino , Humanos , Persona de Mediana Edad
8.
Hepatogastroenterology ; 53(69): 426-34, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16795986

RESUMEN

BACKGROUND/AIMS: Liver is the most common site of metastatic disease in colorectal cancer. Superior response rate was demonstrated in trials comparing hepatic arterial administration of cytotoxic agents with systemic chemotherapy. METHODOLOGY: Records of 109 consecutive patients with colorectal carcinoma metastatic to the liver treated by regional chemotherapy, who underwent implantation of a port system into hepatic artery or portal vein tributaries between 1991 and 1999, were reviewed and survival was evaluated using the log-rank test and multivariate analysis (Cox's proportional hazard regression). RESULTS: The median survival from diagnosis was 24 months. Survival was significantly longer for patients treated by radical resection, and patients treated in 1997-1999. On multivariate analysis, treatment by 6 or more chemotherapy cycles, stage 1 liver metastases, treatment with irinotecan and radical resection were associated with better survival, while the presence of extrahepatic disease had an adverse effect on the risk of death. Extrahepatic spread was subsequently detected in almost half of the patients who had originally isolated liver metastases. CONCLUSIONS: Patients treated by liver resection had the best outcome, while patients with extrahepatic diseases had poor prognosis. The prognosis of patients treated by regional chemotherapy improved significantly with the advent of irinotecan and better selection.


Asunto(s)
Antineoplásicos/administración & dosificación , Neoplasias Colorrectales/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Antraciclinas/administración & dosificación , Antraciclinas/uso terapéutico , Antineoplásicos/uso terapéutico , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Camptotecina/uso terapéutico , Catéteres de Permanencia , Quimioterapia Adyuvante , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/cirugía , Femenino , Hepatectomía , Arteria Hepática , Humanos , Infusiones Intraarteriales , Infusiones Intravenosas , Irinotecán , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Mitomicina/administración & dosificación , Mitomicina/uso terapéutico , Vena Porta , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia
9.
Artículo en Inglés | MEDLINE | ID: mdl-17426786

RESUMEN

BACKGROUND: Recently, the proportion of invasive infections caused by the filamentous fungi of the Aspergillus genus are growing in immunocompromised persons particularly in transplant recipients and neutropenic patients. Unfortunately, laboratory diagnostics of invasive aspergillosis remains extremely difficult, mainly with regard to the sensitivity of the methods and to the correct interpretation of the results in particular. AIM: The aim of this work was to design a standard and reproducible Aspergillus DNA detection method and its validation. The second aim was to practically use this method for diagnosis of Aspergillus DNA in various samples in patients. METHOD: Real-time PCR with two hybridization probes. Amplification and on-line quantification was carried out on a LightCycler 1.5 Instrument. RESULTS: Specificity of the reaction was tested for A. fumigatus, A. flavus, A. niger and A. terreus, and its sensitivity was determined at 5 copies per ml. The reproducibility of the results was comparable to other methods, reported in the literature. Applicability of the real-time PCR was assessed for detection of Aspergillus DNA in 354 various clinical samples taken from 179 patients at risk of invasive aspergillosis over the period of 33 months. Of 354 samples 103 (29.10 %) taken from 65 patients (36.31 %) were evaluated as positive. Over one year, the percentage of positive samples was mostly about 30 % or less per month. CONCLUSIONS: Our results demonstrate the high sensitivity, specificity and reproducibility of this technique, and its usefulness for rapid laboratory diagnosis of invasive aspergillosis.


Asunto(s)
Aspergilosis/diagnóstico , Aspergillus/clasificación , ADN de Hongos/análisis , Adolescente , Adulto , Anciano , Aspergilosis/microbiología , Aspergillus/genética , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad
10.
Toxicol In Vitro ; 19(6): 713-23, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15908174

RESUMEN

Exposure to hexavalent chromium causes various adverse effects including deep skin ulcerations and allergic dermatitis. Because of many potential intracellular targets for hexavalent chromium toxicity, its mechanisms of action are not entirely understood. To investigate the role of the cytoskeleton and mitochondria in this process, primary human dermal fibroblasts were exposed to various concentrations of potassium chromate for 24 h. The followed markers included cell motility, cytoskeletal organization, oxidative stress, mitochondrial activity and activation of the apoptotic cascade. Potassium chromate (1.5-45 microM) induced time- and concentration-dependent cell shrinkage, reorganization of cytoskeleton and loss of motile activity in fibroblasts. In some cells this was followed by membrane blebbing. Dynamic changes in cell morphology were accompanied with the loss of mitochondrial membrane potential, increased oxidative stress and release of cytochrome c. Apoptosis was confirmed by detection of activated caspase-3 and nuclear fragmentation. The results indicate that in fibroblasts hexavalent chromium-induced damage to cytoskeleton and mitochondria might occur concurrently at relatively early stages of exposure. Furthermore, alterations of these targets seem to activate mitochondria-dependent and- independent apoptosis.


Asunto(s)
Actinas/química , Actinas/efectos de los fármacos , Apoptosis/efectos de los fármacos , Cromo/toxicidad , Citoesqueleto/química , Citoesqueleto/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Piel/efectos de los fármacos , Biomarcadores , Caspasa 3 , Caspasas/metabolismo , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Citocromos c/metabolismo , Fibroblastos/enzimología , Humanos , Potenciales de la Membrana/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Piel/citología
11.
J Trace Elem Med Biol ; 18(3): 251-60, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15966574

RESUMEN

Zinc is an important cellular antioxidant. We investigated its role in chromium-induced oxidative stress and apoptosis in human tumor cell line Hep-2. The measured parameters included intracellular labile zinc content (Zinquin-E fluorescence), cell viability (WST-1 assay), oxidative stress (spectrophotometry), mitochondrial potential (flow cytometry), caspase-3 activity, and PARP cleavage (immunofluorescence). We found that Hep-2 cells contain abundant labile zinc stores that may be depleted by the ionophore TPEN or increased by external zinc supplementation. Chromium (VI)-induced cytotoxicity and apoptosis were enhanced in zinc-depleted cells after 24 h, in particular at chromium (VI) concentrations of 50 and 150 micromol/l. On the other hand, elevated levels of labile zinc were able to protect against apoptosis induced by 10 micromol/l chromium (VI) but at higher chromium (VI) concentrations (50 and 150 micromol/l) acted synergistically, significantly enhancing oxidative stress and the course of apoptosis, possibly through oxidative stress and mitochondrial damage.


Asunto(s)
Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Zinc/farmacología , Caspasa 3 , Caspasas/metabolismo , Línea Celular Tumoral , Cromatos/farmacología , Activación Enzimática , Colorantes Fluorescentes , Humanos , Potenciales de la Membrana/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Poli(ADP-Ribosa) Polimerasas/metabolismo , Compuestos de Potasio/farmacología , Quinolonas , Compuestos de Tosilo
12.
Tumori ; 91(1): 19-23, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15850000

RESUMEN

AIMS AND BACKGROUND: Liver metastases in patients with sarcoma are rare and associated with a poor prognosis. The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited. METHODS: Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period. Since the experience was limited, a pooled analysis of reports with data on survival of 22 individual patients was performed. RESULTS: None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients. The median survival was 20 months. In the pooled analysis, partial response was observed in 10 of 21 assessable patients (48%) and median survival was 20 months. The survival was significantly longer in responding patients compared to nonresponders (35 vs 14 months; logrank test, P = 0.009). CONCLUSIONS: Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver. More promising results have been reported for chemoembolization. The survival of responding patients seems to be better compared to non-responders.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Arteria Hepática , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Sarcoma/tratamiento farmacológico , Sarcoma/secundario , Adulto , Anciano , Femenino , Humanos , Infusiones Intraarteriales , Neoplasias del Yeyuno/patología , Masculino , Persona de Mediana Edad , Neoplasias del Recto/patología , Neoplasias Retroperitoneales/patología , Estudios Retrospectivos , Neoplasias Gástricas/patología , Análisis de Supervivencia , Resultado del Tratamiento
13.
Acta Medica (Hradec Kralove) ; 48(3-4): 165-72, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16640032

RESUMEN

The aim of our study was to describe histopathology of the peripheral nerve after its circular release followed by embedding in different environs. We operated on 18 male rats divided into 3 groups. In the first group right femoral nerve was surgically released. In the second group the nerve was enveloped by the subcutaneous fat flap. In the third one the nerve was wrapped up by the skeletal muscle. Six weeks later the animals were killed by exsanguination. The femoral nerve, in the first group, did not show any pathological changes. In the second group 3 animals appeared normal or nearly normal, nevertheless in 3 of them perineural fibrosis and axonal degeneration were observed. Histological reaction in the third group disclosed dispersed axonal injury. Our experiments using rat model imitate situation in humans. The results obtained will help us in making meaningful decision when performing peripheral nerve injury.


Asunto(s)
Nervio Femoral/cirugía , Nervio Femoral/ultraestructura , Animales , Masculino , Fibras Nerviosas/ultraestructura , Ratas , Ratas Wistar
14.
Ann N Y Acad Sci ; 1010: 520-4, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15033783

RESUMEN

The aim of the study was to investigate the mechanism of action of somatostatin analogues (SSA), ionizing radiation, and their combination on pituitary adenoma cells with special emphasis on proliferative and apoptotic activity. In the 14 GH-secreting adenomas pretreated with SSA before surgery, more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis than in the reference group of 17 unpretreated adenomas. The proliferative Ki-67 labeling index was significantly lower in the treated group (median 1.6 per 1000) than in the untreated patients (median 5.0 per 1000). Apoptosis was detected in only 2 of the 14 pretreated adenomas, and it was more frequent (9/17) and more prominent in the untreated group. In cell lines, the SSA had minimal antiproliferative effect, and they were unable to induce apoptosis. Ionizing radiation at doses of 5-20 Gy induced apoptosis in the corticotroph cell line AtT20 with no cell-cycle block. In the somatotroph GH3 cell line, the early (premitotic) apoptosis was detectable using only a high dose of 200 Gy; after irradiation with doses of 20-50 Gy, apoptosis appeared with the latency of 48-72 hours, and was preceded by cell-cycle arrest in the G(2)/M phase. The treatment with somatostatin-14 during irradiation increased the percentage of apoptotic cells in culture 10 days after irradiation (11% versus 3% using 20 Gy).


Asunto(s)
Adenoma/patología , Adenoma/cirugía , Apoptosis/fisiología , Neoplasias Hipofisarias/patología , Neoplasias Hipofisarias/cirugía , Adenoma/radioterapia , Apoptosis/efectos de la radiación , Biomarcadores de Tumor/análisis , Ciclo Celular/efectos de la radiación , División Celular , Humanos , Neoplasias Hipofisarias/radioterapia
15.
Cancer Biother Radiopharm ; 17(5): 545-52, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12470424

RESUMEN

BACKGROUND: Liver is the most common site of metastatic disease. Hepatic arterial infusion (HAI) of cytotoxic drugs may achieve high objective response rate. METHODS: Peripheral blood mononuclear cells were obtained by leukapheresis after stimulation with subcutaneous GM-CSF in six patients and with subcutaneous interleukin-2 (IL-2) in four patients, all with nonresectable hepatic metastases not responsive to conventional regimens. After the cytokine stimulation, the cells were administered by HAI either alone, or after HAI of melphalan (50 mg). RESULTS: Mean number of 23.1 +/- 4.6 x 10(9) and 19.0 +/- 9.7 x 10(9) mononuclear cells were obtained through leukapheresis after GM-CSF and IL-2 priming, respectively. Significant cytotoxic activity was observed only after short IL-2 stimulation. A marked decrease in tumor markers was observed in two patients treated by combination of melphalan and activated leukocytes. CONCLUSIONS: HAI is a technically feasible way of regional delivery of a high number of activated leukocytes obtained after short ex vivo activation.


Asunto(s)
Arteria Hepática , Inmunoterapia Adoptiva , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/terapia , Biomarcadores de Tumor/análisis , Transfusión de Componentes Sanguíneos , Femenino , Humanos , Interleucina-2/farmacología , Leucocitos , Activación de Linfocitos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Trasplante Autólogo
16.
Hepatogastroenterology ; 49(46): 900-6, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12143237

RESUMEN

BACKGROUND/AIMS: The prognosis of biliary tract cancers is poor. The aim of the present report was to analyze retrospectively the effectiveness of regional chemotherapy in patients with biliary tract cancers treated at a single institution. METHODOLOGY: Thirty-two patients with biliary tract cancers, 17 patients with cholangiocarcinoma and 15 patients with gallbladder carcinoma, were treated by regional administration of the chemotherapy, usually the combination of 5-fluorouracil, cisplatin and folinic acid. Eighteen patients with inoperable tumors received no surgical treatment, 10 patients were treated by palliative resection (cohort B), and 4 patients received radical surgery (cohort C). RESULTS: The median survival of the patients is (mean +/- standard deviation) 14 +/- 17+ (median 7+) months for cohort A patients, 22 +/- 17+ (median 17+) months for cohort B patients, and 32 +/- 4+ (median 33+) months for cohort C patients. One-year survival was 38% (6 out of 16 patients) for cohort A, 80% (8 out of 10 patients) for cohort B, and 100% (4 out of 4 patients for cohort C). Two-year survival was 15% (2 out of 13) for cohort A, 30% (3 out of 10) for cohort B, and 100% (4 out of 4) for cohort C. One out of 12 patients (8%) in cohort A and 1 out of 10 patients (10%) in cohort B survived more than 5 years. After intraarterial chemotherapy, a significant increase was observed in the absolute numbers of CD3+, CD3+CD8+ and CD8+CD28+ lymphocytes, as well as an increase in CD3+CD4+ and natural killer lymphocytes. CONCLUSIONS: Regional chemotherapy is active in controlling the disease, and seems to result in prolongation of survival in patients with biliary tract cancer. Administration of regional chemotherapy is also associated with a rise of circulating lymphocyte numbers.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Sistema Biliar/tratamiento farmacológico , Colangiocarcinoma/tratamiento farmacológico , Infusiones Intraarteriales , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias del Sistema Biliar/mortalidad , Neoplasias del Sistema Biliar/cirugía , Quimioterapia Adyuvante , Colangiocarcinoma/mortalidad , Colangiocarcinoma/cirugía , Cisplatino/administración & dosificación , Estudios de Cohortes , Terapia Combinada , República Checa , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Leucovorina , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Cuidados Paliativos , Estudios Retrospectivos , Análisis de Supervivencia
17.
Tumori ; 90(4): 428-34, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15510990

RESUMEN

AIMS AND BACKGROUND: Gastric cancer is associated with high mortality. Although the liver is a common site of metastases in this tumor, the experience with liver-directed therapies is limited. METHODS: We report a single-center experience involving four patients with liver metastases from gastric cancer treated by hepatic arterial infusion (HAI). In addition, we performed a search for reports on HAI in gastric cancer metastatic to the liver and used the studies with data on survival of individual patients for a pooled analysis. RESULTS: Among three valuable patients, one had a complete response, one had stable disease and one had progressive disease. The patient with complete response is still alive 41 months after the diagnosis of liver metastases, while the other patients died 6, 22 and 31 months after the diagnosis. Objective responses were observed in 48% of the 25 patients in the pooled analysis. Objective response and limited hepatic involvement were independent predictors of survival in these patients. CONCLUSIONS: Although isolated liver involvement in metastatic gastric cancer is rare, HAI seems to be similarly effective in these patients as in patients with liver metastases from colorectal cancer. The prognosis is significantly better in gastric cancer patients who have limited hepatic involvement and attain an objective response after HAI.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Quimioembolización Terapéutica , Arteria Hepática , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Neoplasias Gástricas/patología , Anciano , Gastrectomía/métodos , Humanos , Infusiones Intraarteriales , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Gástricas/cirugía , Resultado del Tratamiento
18.
Artículo en Checo | MEDLINE | ID: mdl-16106734

RESUMEN

It is known that the subependymal layer (SEL) of the lateral brain ventricles' wall is a source of neural stem cells (NSCs) of adult mammalian brain including the human brain. The NSCs in relation to the striatum differentiate only into glial phenotype. Therefore we focused on proliferative activity of NSCs and precursors in the SEL and on the course of their differentiation into the astrocytes in reaction to the neurodegenerative process in the striatum like in Huntington's disease. Increased gliogenesis, differentiation of newly generated cells and their ability to migrate into the striatum were evaluated in two groups of the rats surviving 1 and 3 months after the application of the neurotoxic (ibotenic) acid into the striatum. For evaluation of the proliferative activity we compared the results obtained using two proliferative markers--Bromodeoxyuridine (BrdU) and Ki-67. Characterization of newly generated cells and of their differentiation was based on the detection using the following antibodies: Nestin (a marker for NSCs and precursors), GFAP (detection of astrocytes), also the double-staining method with BrdU and GFAP.


Asunto(s)
Diferenciación Celular , Ventrículos Cerebrales/patología , Cuerpo Estriado/patología , Enfermedades Neurodegenerativas/patología , Neuronas/patología , Células Madre/patología , Animales , Astrocitos/patología , División Celular , Cuerpo Estriado/efectos de los fármacos , Epéndimo/citología , Ácido Iboténico , Masculino , Enfermedades Neurodegenerativas/inducido químicamente , Ratas , Ratas Long-Evans , Células Madre/citología
20.
Support Care Cancer ; 15(4): 445-9, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17103198

RESUMEN

INTRODUCTION: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma after failure of standard chemotherapy. Rare infusion reactions that resulted in the cessation of therapy have been described after cetuximab administration. CASE DESCRIPTION: We have observed severe infusion reactions accompanied by a loss of consciousness in two patients. The patients were transferred to intensive care unit, and the treatment was continued after administration of corticosteroids under careful monitoring of vital signs without any further serious reactions. In both cases, benefit of therapy with cetuximab could be demonstrated. CONCLUSION: This experience indicates that cetuximab can be continued in patients who experience infusion reactions. Surveillance in the intensive care unit is mandatory during readministration of the drug.


Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Antineoplásicos/administración & dosificación , Dexametasona/uso terapéutico , Hipersensibilidad a las Drogas/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Bombas de Infusión/efectos adversos , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/secundario , Anciano , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales Humanizados , Antineoplásicos/efectos adversos , Cetuximab , Humanos , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Neoplasias del Colon Sigmoide/tratamiento farmacológico , Neoplasias del Colon Sigmoide/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA